Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that people with diabetes are not impacted by the shortage of Ozempic.

The Department has worked intensively with pharmaceutical industry, NHS England, the Medicines and Healthcare products Regulatory Agency (MHRA) and others in the supply chain to largely resolve the supply issues with GLP-1 receptor agonists (GLP-1 RAs), including Ozempic (semaglutide). Currently all strengths and presentations of Ozempic are available. We continue to monitor the supply of GLP-1 RA’s closely to ensure these medicines remain available for patients. Any patient concerned about their condition, or access to these medications, should speak to their prescriber in the first instance.